[Clostridioides difficile infection: various therapeutic approaches].

In 2021, the European and American Infectious Diseases Societies published new guidelines for the treatment of Clostridiodes difficile colitis. They have opted for a change in practice with fidaxomicin being recommended as the first line of treatment, and vancomycin as a second choice. Metronidazole remains recommended only in cases where other treatments are not available. These choices have not been endorsed by the Swiss Infectious Diseases Society, which still proposes metronidazole as first-line treatment. As a matter of fact, this inexpensive treatment still presents a satisfactory efficacy on the strains of Clostridoides difficile found in Switzerland in the context of patients without risk factors and with low probability of relapse.